BP13944 is a potential small-molecule inhibitor discovered through high-throughput screening; it effectively inhibits the expression of dengue virus (DENV) replicons with an EC50 of 1.03±0.09 μM; it suppresses replication or viral RNA synthesis of all four DENV serotypes but shows no activity against Japanese encephalitis virus; it likely targets the DENV NS3 protease, as an E66G amino acid substitution in the NS3 protease domain confers resistance to BP13944; due to the lack of effective dengue vaccines or antiviral therapies, BP13944 represents a promising candidate for the development of anti-dengue therapeutics.